Vol 15, No 3 (2019)
Review paper
Published online: 2019-06-26
ALK, ROS1 and EGFR next-generation tyrosine kinase inhibitors in advanced non-small-cell lung cancer
Oncol Clin Pract 2019;15(3):150-157.
Abstract
Non-small-cell lung cancer (NSCLC) is the most common cancer in men and the second most common in fe- males. In previous years the significance of some molecular disorders in pathogenesis NSCLC was proven and the value of targeted therapies in the treatment of patients was documented. In subjects with abnormalities of EGFR, ALK and ROS1 genes, appropriate tyrosine kinase inhibitors (TKIs) may be used. The use of these drugs in the first and second treatment lines has affected a significant improvement in the prognosis in this subgroup of patients. The article presents mechanisms of action and data on the clinical value of lorlatinib, brigatinib and dacomitinib in the treatment of patients with advanced lung of lung cancer.
Keywords: non-small-cell lung cancerkinase inhibitorslorlatinibbrigatinibdacomitinib
References
- http://www.who.int/en/news-room/fact-sheets/detail/cancer.
- Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740-801.
- Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017; 18(12): 1590–1599.
- Solomon B, Shaw A, Ou S, et al. OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK + /ROS1 + Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 2017; 12(11): S1756.
- Akamine T, Toyokawa G, Tagawa T, et al. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. Onco Targets Ther. 2018; 11: 5093–5101.
- https://www.drugs.com/clinical_trials/pfizer-s-next-generation-alk-ros1-inhibitor-lorlatinib-granted-breakthrough-therapy-designation-fda-17423.html.
- https://clinicaltrials.gov/ct2/show/record/NCT03052608.
- Nguyen TD, DeAngelis LM. Brain metastases. Neurol Clin. 2007; 25(4): 1173–92, x.
- Collier TL, Normandin MD, Stephenson NA, et al. Synthesis and preliminary PET imaging of C and F isotopologues of the ROS1/ALK inhibitor lorlatinib. Nat Commun. 2017; 8: 15761.
- Millett RL, Elkon JM, Tabbara IA. Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. Anticancer Res. 2018; 38(9): 4969–4975.
- Krawczyk P. Mechanizmy oporności na leki z grupy IKT. Onkol Prakt Klin Edu. 2016; 2(supl B): B17.
- Shaw A, Martini JF, Besse B, et al. Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations. Cancer Research. 2018; 78(13 Supplement): CT044–CT044.
- Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016; 374(1): 54–61.
- Zhang S, Anjum R, Squillace R, et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016; 22(22): 5527–5538.
- Jain RK, Chen H. Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. Lung Cancer (Auckl). 2017; 8: 169–177.
- https://www.ema.europa.eu/documents/product-information/alunbrig-epar-product-information_pl.pdf.
- Gettinger S, Bazhenova L, Langer C, et al. Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. The Lancet Oncology. 2016; 17(12): 1683–1696.
- Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 35(22): 2490–2498.
- Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21): 2027–2039.
- Janne PA. Boss DS. Camididge DR Phase I Dose-escalation of the Pan-HER Inhibitor PF299804, in Patients with Advanced Malignant Solid Tumors Clin Cancer Res. 2011; 17(5): 1131–9.
- Jänne P, Ou SH, Kim DW, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. The Lancet Oncology. 2014; 15(13): 1433–1441.
- Mok TS, Wu YL, Thongprasert SI, et al. Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med. 2009; 361(10): 947–57.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2): 123–132.
- Sequist L, Yang JH, Yamamoto N, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations. Journal of Clinical Oncology. 2013; 31(27): 3327–3334.
- Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11): 1454–1466.
- Mok TS, Cheng Y, Zhou X, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018; 36(22): 2244–2250.